ImmunoVaccine Technologies Receives $3 Million From ACOA



    HALIFAX, Jan. 21 /CNW/ - ImmunoVaccine Technologies Inc. (IVT), a
clinical stage vaccine development company, will receive $3 Million from the
Atlantic Canada Opportunities Agency (ACOA), under the Atlantic Innovation
Fund (AIF). This funding will enable IVT to undertake a $6 million project to
develop new potent immune enhancement systems.
    "Having ACOA recognize the market potential of our innovative vaccine
platform is a tremendous boost," commented Brian Lowe, Vice President of IVT.
"This funding will enable us, over the next three years, to create novel
vaccines for the treatment of cancer and infectious diseases.
    This funding announcement is the maximum grant awarded to a private
company under Round V of the AIF. The funds will further IVT's research
collaborations and commercialization opportunities with pharmaceutical
companies worldwide.
    Atlantic Innovation Fund investments were announced earlier today by The
Honourable Peter MacKay, Minister of National Defence and Minister of the
Atlantic Canada Opportunities Agency. The Atlantic Innovation Fund is designed
to increase leading edge research and development (R&D) in Atlantic Canadian
research facilities, leading to the launch of new ideas, products, processes
and services.

    About the VacciMax(R) Platform

    ImmunoVaccine Technologies Inc. (IVT) has developed a breakthrough
vaccine-enhancement technology - the VacciMax(R) platform. It is comprised of
a mixture of liposomes and adjuvants. The VacciMax(R) platform is able to
stimulate an earlier, more powerful, long lasting immune response that could
provide a new way to treat a wide range of diseases.
    The opportunities for market applications and medical benefits for the
VacciMax(R) platform are broad, and include prostate, breast, cervical,
ovarian, colon and lung cancer treatments, as well as vaccines for pandemic
influenza and other infectious diseases. www.immunovaccine.com




For further information:

For further information: Brian Lowe, Vice President IVT, (902) 492-1819,
bl.ivt@immunovaccine.com; Jennifer Ayotte, Communications, (902) 209-4704,
jayotte@impactcommunications.ca

Organization Profile

IMMUNOVACCINE TECHNOLOGIES INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890